M&A Deal Summary

Progenics Pharmaceuticals Acquires Molecular Insight Pharmaceuticals Inc

On January 22, 2013, Progenics Pharmaceuticals acquired healthcare services company Molecular Insight Pharmaceuticals Inc for 106M USD

Acquisition Highlights
  • This is Progenics Pharmaceuticals’ 1st transaction in the Healthcare Services sector.
  • This is Progenics Pharmaceuticals’ largest (disclosed) transaction.
  • This is Progenics Pharmaceuticals’ 1st transaction in the United States.
  • This is Progenics Pharmaceuticals’ 1st transaction in Massachusetts.

M&A Deal Summary
Date 2013-01-22
Target Molecular Insight Pharmaceuticals Inc
Sector Healthcare Services
Buyer(s) Progenics Pharmaceuticals
Deal Type Add-on Acquisition
Deal Value 106M USD
Advisor(s) Torreya Partners LLC (Financial)

Target

Molecular Insight Pharmaceuticals Inc

Cambridge, Massachusetts, United States
Molecular Insight Pharmaceuticals, Inc., a clinical-stage private biotechnology company with a small molecule chemistry pipeline aimed at enhancing cancer treatment.

Search 200,577 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Progenics Pharmaceuticals

Tarrytown, New York, United States
Category Company
Founded 1986
Sector Life Science
Employees79
Revenue 16M USD (2018)
DESCRIPTION

Progenics Pharmaceuticals, Inc. is a pharmaceutical company provides medicines to treat disease, focusing on cancer and related conditions with a pipeline that includes product candidates in preclinical through late-stage development. Progenics Pharmaceuticals was founded in 1986 and is based in New York City, New York.

DEAL STATS #
Overall 1 of 1
Sector (Healthcare Services) 1 of 1
Type (Add-on Acquisition) 1 of 1
State (Massachusetts) 1 of 1
Country (United States) 1 of 1
Year (2013) 1 of 1
Size (of disclosed) 1 of 1
Mergr

Product

Company

Legal